Skip to main content

Advertisement

Log in

Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

Staging laparoscopy is considered useful for determining treatment plans for advanced pancreatic cancer. However, the indications for staging laparoscopy are not clear. This study aimed to evaluate the safety of staging laparoscopy and its usefulness for detecting distant metastases in patients with pancreatic cancer.

Methods

A total of 146 patients with pancreatic cancer who underwent staging laparoscopy between 2013 and 2019 were analyzed. Staging laparoscopy was performed in all pancreatic cancer patients in whom surgery was considered possible.

Results

In this cohort, 42 patients (29%) were diagnosed with malignant cells on peritoneal lavage cytology, 9 (6%) had peritoneal dissemination, and 11 (8%) had liver metastases. A total of 48 (33%) had radiologically negative metastases. On a multivariate analysis, body and tail cancer [odds ratio (OR) 5.00, 95% confidence interval (CI) 2.15–11.6, p < 0.001], high CA19-9 level [OR 4.04, 95% CI 1.74–9.38, p = 0.001], and a resectability status of unresectable (OR 2.31, 95% CI 1.03–5.20, p = 0.04) were independent risk factors for radiologically negative metastases.

Conclusions

Staging laparoscopy can be safely performed and is useful for the diagnosis of radiologically negative metastases. Staging laparoscopy should be routinely performed for the accurate diagnosis of pancreatic cancer patients before pancreatectomy and/or local treatment, such as radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1 
Fig. 2 
Fig. 3 

Similar content being viewed by others

References

  1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet (London, England). 2004;363(9414):1049–57.

    Article  CAS  Google Scholar 

  2. Siegel RL, Miller KD. Jemal A (2020) cancer statistics. CA Cancer J Clin. 2020;70(1):7–30.

    Article  Google Scholar 

  3. Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, et al. Japan pancreatic cancer registry; 30th year anniversary: Japan pancreas society. Pancreas. 2012;41(7):985–92.

    Article  Google Scholar 

  4. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, et al. Pancreatic cancer registry in Japan: 20 years of experience. Pancreas. 2004;28(3):219–30.

    Article  Google Scholar 

  5. Karabicak I, Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, et al. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat sci. 2016;23(12):750–5.

    Article  Google Scholar 

  6. Sell NM, Fong ZV, Del Castillo CF, Qadan M, Warshaw AL, Chang D, et al. Staging laparoscopy not only saves patients an incision, but may also help them live longer. Ann Surg Oncol. 2018;25(4):1009–166.

    Article  Google Scholar 

  7. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the national cancer database. J Am Coll Surg. 1999;189(1):1–7.

    Article  CAS  Google Scholar 

  8. Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr. The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol. 2006;17(2):189–99.

    Article  CAS  Google Scholar 

  9. Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19(5):1644–62.

    Article  Google Scholar 

  10. D'Angelo F, Antolino L, Farcomeni A, Sirimarco D, Kazemi Nava A, De Siena M, et al. Neoadjuvant treatment in pancreatic cancer: evidence-based medicine? A systematic review and meta-analysis. Med Oncol. 2017;34(5):85.

    Article  Google Scholar 

  11. Motoi F, Ishida K, Fujishima F, Ottomo S, Oikawa M, Okada T, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013;20(12):3794–801.

    Article  Google Scholar 

  12. Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, et al. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterology. 2018;54(2):194–203.

    Article  Google Scholar 

  13. Motoi F, Unno M, Takahashi H, Okada T, Wada K, Sho M, et al. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese society of hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci. 2014;21(2):148–58.

    Article  Google Scholar 

  14. Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, Honda G, et al. Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer. 2019;19(1):252.

    Article  Google Scholar 

  15. Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019;49(2):190–4.

    Article  Google Scholar 

  16. Unno M, Hata T, Motoi F. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis. Surg Today. 2019;49(4):295–9.

    Article  Google Scholar 

  17. Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, Yamaki S, et al. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World J Surg Oncol. 2016;14(1):14.

    Article  Google Scholar 

  18. Ta R, O'Connor DB, Sulistijo A, Chung B, Conlon KC. The role of staging laparoscopy in resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis. Dig Surg. 2018;36(3):251–60.

    Article  Google Scholar 

  19. Conlon KC, Dougherty E, Klimstra DS, Coit DG, Turnbull AD, Brennan MF. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg. 1996;223(2):134–40.

    Article  CAS  Google Scholar 

  20. Network NCC. NCCN Clinical Practice Guidelines in oncology pancreatic adenocarcinoma Version 1. https://wwwnccnorg/professionals/physician_gls/pdf/pancreaticpdf 2019.

  21. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2):173–80.

    Article  Google Scholar 

  22. Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 2016;7(7):Cd009323.

    PubMed  Google Scholar 

  23. Ferrone CR, Haas B, Tang L, Coit DG, Fong Y, Brennan MF, et al. The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrointest Surg. 2006;10(10):1347–53.

    Article  Google Scholar 

  24. Satoi S, Murakami Y, Motoi F, Uemura K, Kawai M, Kurata M, et al. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. J Gastrointest Surg. 2015;19(1):6–14.

    Article  Google Scholar 

  25. Yamada S, Fujii T, Kanda M, Sugimoto H, Nomoto S, Takeda S, et al. Value of peritoneal cytology in potentially resectable pancreatic cancer. Br J Surg. 2013;100(13):1791–6.

    Article  CAS  Google Scholar 

  26. White R, Winston C, Gonen M, D'Angelica M, Jarnagin W, Fong Y, et al. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg. 2008;206(3):445–50.

    Article  Google Scholar 

  27. Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg. 2019. https://doi.org/10.1097/SLA.0000000000003284.

    Article  Google Scholar 

  28. Cloyd JM, Chen HC, Wang X, Tzeng CD, Kim MP, Aloia TA, et al. Chemotherapy versus chemoradiation as preoperative therapy for resectable pancreatic ductal adenocarcinoma: a propensity score adjusted analysis. Pancreas. 2019;48(2):216–22.

    Article  CAS  Google Scholar 

  29. Satoi S, Yanagimoto H, Yamamoto T, Ohe C, Miyasaka C, Uemura Y, et al. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy. Surg Today. 2017;47(1):84–91.

    Article  CAS  Google Scholar 

  30. Natsume S, Shimizu Y, Senda Y, Hijioka S, Matsuo K, Ito S, et al. Conversion surgery only for highly selected patients with unresectable pancreatic cancer: a satisfactory outcome in exchange for a lower resection rate. Surg Today. 2019;49(8):670–7.

    Article  Google Scholar 

  31. Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today. 2019;49(11):894–906.

    Article  Google Scholar 

  32. Hariharan D, Constantinides VA, Froeling FE, Tekkis PP, Kocher HM. The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of pancreatico-biliary cancers–a meta-analysis. Eur J Surg Oncol. 2010;36(10):941–8.

    Article  CAS  Google Scholar 

  33. Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, et al. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. HPB. 2015;17(2):131–9.

    Article  Google Scholar 

  34. Morris S, Gurusamy KS, Sheringham J, Davidson BR. Cost-effectiveness of diagnostic laparoscopy for assessing resectability in pancreatic and periampullary cancer. BMC Gastroenterol. 2015;15:44.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported, in part, by JSPS KAKENHI Grant number 19K18107.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tatsuyuki Takadate.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takadate, T., Morikawa, T., Ishida, M. et al. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Surg Today 51, 686–694 (2021). https://doi.org/10.1007/s00595-020-02121-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-020-02121-4

Keywords

Navigation